A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects-Reference-Cited by-同舟云学术

A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects

Published:2022-01-06 Issue:1 Volume:22 Page:71-87
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Jeon Yoomin^ORCID,Lee Nora^ORCID,Baek Seungjae,Choi JaeDuk,Jhee Stanford^ORCID,Lee Howard^ORCID

Funder

Hanmi Pharmaceutical Co., Ltd.,

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40268-021-00379-8.pdf

Reference29 articles.

1. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916–24.

2. Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia. J Immunol. 2015;195:1341–9.

3. Filgrastim. The American Society of Health-System Pharmacist. https://www.drugs.com/monograph/filgrastim.html. Accessed 23 Jul 2021.

4. Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis. Cytokine. 2008;42:277–88.

5. Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev. 1996;28:625–58.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilar in Cervical Cancer;Biosimilars for Cancer Treatment;2024

2. New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy;Frontiers in Oncology;2023-01-05

3. Application of Elastin-like Polypeptide in Tumor Therapy;Cancers;2022-07-28